Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | -0.30% | -19.32% | +8.20% |
Financials (USD)
Sales 2024 * | 70.95M | Sales 2025 * | 95.42M | Capitalization | 173M |
---|---|---|---|---|---|
Net income 2024 * | -31M | Net income 2025 * | -21M | EV / Sales 2024 * | 2.43 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.81 x |
P/E ratio 2024 * |
-6.06
x | P/E ratio 2025 * |
-11
x | Employees | 100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.42% |
Latest transcript on G1 Therapeutics, Inc.
1 day | -0.30% | ||
1 week | -19.32% | ||
1 month | -20.10% | ||
3 months | -11.53% | ||
6 months | +65.00% | ||
Current year | +8.20% |
Managers | Title | Age | Since |
---|---|---|---|
Jack Bailey
CEO | Chief Executive Officer | 59 | 20-03-11 |
John Umstead
DFI | Director of Finance/CFO | - | 17-12-31 |
Rajesh K. Malik
CTO | Chief Tech/Sci/R&D Officer | 65 | 14-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Muir
BRD | Director/Board Member | 65 | 15-08-31 |
Cynthia Flowers
BRD | Director/Board Member | 64 | 18-06-06 |
Norman Sharpless
FOU | Founder | 57 | 08-05-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.01% | 430 M€ | -.--% | ||
0.01% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3.3 | -0.30% | 677,169 |
24-05-30 | 3.31 | -0.90% | 847,146 |
24-05-29 | 3.34 | -1.76% | 1,020,711 |
24-05-28 | 3.4 | -16.87% | 2,794,137 |
24-05-24 | 4.09 | -3.08% | 711,392 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.20% | 173M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- GTHX Stock